Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL)

The purpose of this phase 3, randomized, multicenter study is to compare VB-111 and paclitaxel to placebo and paclitaxel in adult patients with Recurrent Platinum-Resistant Ovarian Cancer.
Ovarian
Phase III
Adults
Chemotherapy - cytotoxic, Gene Therapy, Mol. targeted/Immunotherapy/Biologics
Obadenovec (VB-111), Paclitaxel
Crispens, Marta
International
Vanderbilt University
08-22-2019
Treatment
VICCGYN18180
NCT03398655

Eligibility

Not Available
Not Available
NO
Inclusion Criteria:

Female patients ?18 years of age

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: